Moderna And Merck Announce mRNA-4157 (V940) In Combination With KEYTRUDA Demonstrated A Statistically Significant And Clinically Meaningful Improvement In Distant Metastasis-Free Survival In Patients With High-Risk Stage III/IV Melanoma
Portfolio Pulse from Benzinga Newsdesk
Moderna and Merck announced that their mRNA-4157 (V940) in combination with KEYTRUDA showed a statistically significant and clinically meaningful improvement in distant metastasis-free survival in high-risk stage III/IV melanoma patients.
June 05, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA combined with Moderna's mRNA-4157 (V940) demonstrated significant improvement in high-risk melanoma patients.
The positive results from the combination of KEYTRUDA and mRNA-4157 (V940) in high-risk melanoma patients indicate a potential new treatment option. This could lead to increased demand for Merck's KEYTRUDA, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 50
POSITIVE IMPACT
Moderna's mRNA-4157 (V940) combined with Merck's KEYTRUDA showed significant improvement in high-risk stage III/IV melanoma patients.
The positive results from the combination of mRNA-4157 (V940) and KEYTRUDA in high-risk melanoma patients indicate a potential new treatment option. This could lead to increased demand for Moderna's mRNA-4157 (V940), positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 50